A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
about
Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicityA combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effectsProtein fragment domains identified using 2D gel electrophoresis/MALDI-TOF.Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor modelInhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.Topical application of recombinant calreticulin peptide, vasostatin 48, alleviates laser-induced choroidal neovascularization in rats.Vasostatin inhibits VEGF-induced endothelial cell proliferation, tube formation and induces cell apoptosis under oxygen deprivation.Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis.Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models.Angiogenic and antiangiogenic gene therapy.Caffeine-induced endothelial cell death and the inhibition of angiogenesis.Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanismNano to micro delivery systems: targeting angiogenesis in brain tumors.Calreticulin, a therapeutic target?Plasmid-encoding vasostatin inhibited the growth and metastasis of human hepatocellular carcinoma cells.Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules.Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin.Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior.Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice.Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization.Calreticulin expression in neuroblastoma--a novel independent prognostic factor.
P2860
Q24648175-A0D089DB-9289-4BF0-9F41-650458BFA7C8Q30443978-91FA23DF-05BE-476F-8EAF-055E6EAC7210Q33245462-40B2FAE8-8942-4B3A-8F8B-5C310CA80259Q33378960-21F11ECD-B44C-4FE9-AFEF-182353658E07Q33505319-A638B6AD-F83D-4637-97EB-D68B84375B87Q33573595-0EDB1E14-7CCF-410A-B26E-1317EF8F11D5Q33580573-3DAFDB83-E2EB-402C-B5A9-7A4AA5F7B0EAQ35230265-8BC83789-7D37-48BE-86D0-CAA4744E8852Q35870139-3A796153-FE6A-4F49-9A6F-C5503F0237A9Q36288905-2E09C0FB-82C0-4F57-8878-3A09DB58A555Q36737785-25F9C81C-3222-4E32-850B-A4A4222C25FAQ36927348-6F94EB94-7BFA-4323-AAB7-32BB09C5AA13Q37798870-BA707232-5773-4E69-B5D1-60598A65D41DQ38766974-A6276EED-D7B2-48A4-9600-4EDE074CAA95Q38977768-B142878F-7A83-4171-9435-2A463A3E3C98Q39497260-8BD8DB9B-7359-4991-A6A9-C3C147DDBB00Q40312679-389A11E5-917E-4E79-9D5A-E4EAE5701D5BQ40350159-78E05167-68F6-4240-94D0-77F847EE1F63Q40351516-E5A6B346-C2A3-4DD8-BE0C-A88925573EEEQ45857995-ED7494AA-BDF7-4E3A-840E-891FC5C46E69Q47556217-BCE44EDF-2331-42D0-AB39-9F41D422F881Q54683852-CC676916-0CB3-4E26-8B3A-09D2785E324F
P2860
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
@en
type
label
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
@en
prefLabel
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
@en
P2093
P2860
P356
P1433
P1476
A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.GT.3301788
P577
2002-09-01T00:00:00Z
P5875
P6179
1040644216